Lucas V A Boersma
Overview
Explore the profile of Lucas V A Boersma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reijrink-de Boer M, Wolsink I, Frenaij I, Beukema K, Brouns B, van Dijk V, et al.
Neth Heart J
. 2025 Feb;
33(3):85-92.
PMID: 39932623
Background: To detect recurrent atrial fibrillation (AF) after pulmonary vein isolation (PVI), different methods can be used, ranging from incidental electrocardiograms (ECGs) to rhythm monitoring with implantable loop recorders. We...
2.
Potpara T, Grygier M, Haeusler K, Nielsen-Kudsk J, Berti S, Genovesi S, et al.
Thromb Haemost
. 2024 Dec;
PMID: 39657795
Many patients with atrial fibrillation (AF) who are in need of stroke prevention are not treated with oral anticoagulation or discontinue treatment shortly after its initiation. Despite the availability of...
3.
Olde Nordkamp L, Pepplinkhuizen S, Ghani A, Boersma L, Kuschyk J, El-Chami M, et al.
Circ Arrhythm Electrophysiol
. 2024 Dec;
17(12):e012836.
PMID: 39624908
Background: Inappropriate therapy (IAT) is an undesirable side effect of implantable cardiac defibrillator (ICD) therapy. Early studies with the subcutaneous ICD (S-ICD) showed relatively high inappropriate shock (IAS) rates. The...
4.
Knops R, de Veld J, Ghani A, Boersma L, Kuschyk J, El Chami M, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Nov;
17(11):e010822.
PMID: 39561235
Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome the risk of lead-related complications associated with the transvenous implantable cardioverter-defibrillator (TV-ICD). In contrast to the TV-ICD, the S-ICD is...
5.
Wazni O, Saliba W, Nair D, Marijon E, Schmidt B, Hounshell T, et al.
N Engl J Med
. 2024 Nov;
PMID: 39555822
Background: Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk for stroke. Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding...
6.
Maarse M, Seiffge D, Werring D, Boersma L, Aarnink E, Fierro N, et al.
JAMA Neurol
. 2024 Oct;
PMID: 39374446
Importance: Patients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a...
7.
Friedman P, Murgatroyd F, Boersma L, Manlucu J, Knight B, Clementy N, et al.
Circulation
. 2024 Sep;
151(4):322-332.
PMID: 39327797
Background: Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing...
8.
Sagi V, Murgatroyd F, Boersma L, Manlucu J, Knight B, Leclercq C, et al.
Europace
. 2024 Aug;
26(9).
PMID: 39210643
Aims: The extravascular implantable cardioverter-defibrillator (EV ICD) has been shown to be safe and effective for patients at risk of sudden cardiac death, but little is known about EV ICD...
9.
Breeman K, Knops R, van der Stoel M, Boersma L, Yap S, van Erven L, et al.
Neth Heart J
. 2024 Aug;
32(10):356-362.
PMID: 39158682
Introduction: Conventional implantable cardioverter-defibrillators (ICDs) and pacemakers carry a risk of pocket- and lead-related complications in particular. To avoid these complications, extravascular devices (EVDs) have been developed, such as the...
10.
Bochem A, Boersma L, van der Crabben S
Neth Heart J
. 2024 Aug;
32(9):332.
PMID: 39158681
No abstract available.